Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001062993-25-012405
Filing Date
2025-07-01
Accepted
2025-07-01 21:21:50
Documents
2
Period of Report
2025-07-01

Document Format Files

Seq Description Document Type Size
1 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES form3.html 3  
1 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES form3.xml 3 4748
2 POWER OF ATTORNEY exhibit24.txt EX-24 5955
  Complete submission text file 0001062993-25-012405.txt   12493
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Issuer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ORUKA THERAPEUTICS, INC. 855 OAK GROVE AVE., SUITE 100 MENLO PARK CA 94025
Business Address
Sandler Laura Lee (Reporting) CIK: 0002075401 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-22873 | Film No.: 251098142